Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of **somatropin** (recombinant human growth hormone) and **platelet-rich plasma (PRP)**, administered primarily via intra-articular injection. Somatropin acts as a systemic growth factor by stimulating growth, cell reproduction, and regeneration, while PRP is an autologous blood-derived product enriched in platelets and a broad array of naturally occurring growth factors, chemokines, and cytokines that locally stimulate tissue regeneration and healing. This combination has been evaluated for regenerative and anti-inflammatory effects, aiming to synergistically enhance tissue repair in musculoskeletal conditions—most notably for osteoarthritis of the knee and other joints—by combining systemic and local trophic effects[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on somatropin + platelet-rich plasma.